Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aneurysm & intracranial embolization cases in Louisiana: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 13% on average (82 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 106 | 42% |
| 2020 | 1 | 78 | 45% |
| 2021 | 0 | 87 |
Aneurysm coiling and flow diversion, AVM and tumor embolization, intracranial stenting. Professional codes (what the surgeon bills): CPT 61624, 61635, 61630.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Louisiana; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Stroke thrombectomy | 10 | 196+0.2%/yr | +0.2%/yr | 0.51.2× | 0% | 250 in 2030+4.2%/yr |
| DBS & VNS |
Aneurysm & intracranial embolization in every state, and its device makers · Every procedure market in Louisiana · Every state · Compare with Florida
| ≈ 150 |
| – |
| 2026 est. | ≈ 160 | – |
| 51% |
| 2022 | 0 | 112 | 54% |
| 2023 | 0 | 75 | 58% |
| 2024 | 7 | 162 | 60% |
| 2025 from claims | – | 150 121–176 | 61% |
| 2026 forecast | – | 161 126–202 | 62% |
| 2027 forecast | – | 173 129–229 | 63% |
| 2028 forecast | – | 187 132–258 | 63% |
| 2029 forecast | – | 202 137–289 | 64% |
| 2030 forecast | – | 217 142–322 | 65% |
In 2025, 100% inpatient hospital.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| +13%/yr |
| 0.5 |
| 0% |
| 2,130 in 2030+12%/yr |
| Virginia | 11 | 407+13%/yr | +13%/yr | 0.4 | 0% | 670 in 2030+8.8%/yr |
| North Carolina | 13 | 383+6.3%/yr | +6.3%/yr | 0.4 | 0% | 640 in 2030+8.8%/yr |
| Tennessee | 9 | 328+6.6%/yr | +6.6%/yr | 0.5 | 0% | 490 in 2030+6.8%/yr |
| Maryland | 10 | 326+15%/yr | +15%/yr | 0.4 | 0% | 570 in 2030+9.9%/yr |
| Georgia | 8 | 323+8.8%/yr | +8.8%/yr | 0.4 | 0% | 940 in 2030+19%/yr |
| Kentucky | 9 | 226+16%/yr | +16%/yr | 0.5 | 0% | 310 in 2030+5.4%/yr |
| Alabama | 6 | 196+34%/yr | +34%/yr | 0.4 | 0% | 300 in 2030+7.4%/yr |
| South Carolina | 9 | 195−0.2%/yr | −0.2%/yr | 0.3 | 0% | 440 in 2030+15%/yr |
| Oklahoma | 2 | 164+3.5%/yr | +3.5%/yr | 0.3 | 0% | 450 in 2030+18%/yr |
| Mississippi | 4 | 119+13%/yr | +13%/yr | 0.3 | 0% | 110 in 2030−1.2%/yr |
| 2 |
| 151−6.2%/yr |
| −6.2%/yr |
| 0.41.1× |
| 0% |
| 1,100 in 2030+39%/yr |
| CSF shunts | 1 | 126−3%/yr | −3%/yr | 0.31.7× | 0% | 260 in 2030+13%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Penumbra leads with 36% of company spending on these surgeons in 2025, +32 pts on 2024.
In 2025, 8 companies reported engagement with Louisiana’s surgeons worth $84K in consulting, speaking, meals and travel tied to these products, about $12K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.